The Professional Home for Oncology Nurses

From TheHill.com: U.S. Representative Mark Green (R-TN) reintroduced a bill seeking to reform prior authorization requirements in Medicare, Medicare Advantage, and Part D prescription drug plans requiring only specialty board certified physicians to make important decisions about treatment. The prior authorization measure is used by insurers to approve the cost of treatment plans, medication, and procedures before a prescription or operation can be obtained or performed.

How much do you know about vaccination for diseases like measles in patients with cancer? Test your knowledge with this quick quiz. 

When nurses experience burnout, it affects patients, too—contributing to implications such as more frequent infections, falls, medication errors, and adverse events, researchers reported in study results published in JAMA Network Open. Additionally, although the COVID-19 pandemic has been blamed for the most recent wave of nurse burnout, the researchers found that “the association with quality of care was increasingly negative over three decades”—long before the pandemic.

Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) is a combination drug that uses hyaluronidase to enhance absorption when administered subcutaneously with nivolumab, a programmed cell death receptor-1–blocking antibody. The U.S. Food and Drug Administration has approved it for multiple indications, offering a new option for many patients with cancer.

In a 2024 study, researchers looked at mortality data for some common and screenable cancers in the United States. Using modeling, they estimated how prevention, screening, and treatment interventions have affected the number of averted deaths from 1975–2020. They found that of the estimated 5.94 million averted deaths, 80% (4.75 million) were attributed to prevention and screening efforts alone.

On March 28, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi^®) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer.